专利检索_ .均聚糖即多糖的主链组成的一个单一的糖例如多聚乙酰神经酸专利检索_ .均聚糖即多糖的主链组成的一个单一的糖例如多聚乙酰神经酸专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
161	Activated sialic acid derivatives for protein derivatisation and conjugation	US13544882	2012-07-09	US08735557B2	2014-05-27	Sanjay Jain; Ioannis Papaioannou; Smita Thobhani
Derivatives of PSAs are synthesized, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.
162	PHARMACEUTICAL COMPOSITIONS COMPRISING MODIFIED FUCANS AND METHODS RELATING THERETO	US13918544	2013-06-14	US20140128340A1	2014-05-08	Christopher Michael Kevin Springate
Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases.
163	Sialic acid derivatives for protein derivatisation and conjugation	US12897523	2010-10-04	US08653255B2	2014-02-18	Sanjay Jain; Peter Laing; Gregory Gregoriadis; Dale Howard Hreczuk-Hirst; Ioannis Papaioannou
Derivatives are synthesized of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
164	Fractionation of charged polysaccharide	US11660133	2005-08-12	US08652334B2	2014-02-18	Sanjay Jain; Ioannis Papaioannou; Peter Laing
Polydisperse and charged polysaccharides are fractionated into low polydispersity fractions (preferably having pd<1.1), each containing species within a narrow range of molecular weights. An aqueous solution of the polydisperse polysaccharides is contacted with an ion exchange resin in a column and the polysaccharides are subjected to selective elution by aqueous elution buffer. The selective elution consists of at least 3 sequential elution buffers having different and constant ionic strength and/or pH and in which the subsequent buffers have ionic strength and/or pH than those of the preceding step. The new preparations are particularly suitable for the production of PSA-derivatised therapeutic agents intended for use in humans and animals.
165	Compositions and methods of aloe polysaccharides	US12985943	2011-01-06	US08604187B2	2013-12-10	Ivan E. Danhof
The present invention describes a method for preparing a polymannan extract from freeze-dried aloe powder. The polymannan extract of the present invention is further used to formulate a sterile injectable formulation for the treatment of one or more cancers, leukemias and lymphomas, prostate cancer, breast cancer, and colon cancer, immune diseases, particularly immune related neoplasms, acquired immune deficiency syndrome, and hepatitis C.
166	COMPOUNDS	US13997017	2011-12-23	US20130315959A1	2013-11-28	Paolo Costantino; Roberto Adamo; Maria Rosaria Romano; Elisa Danieli; Francesco Berti; Emilia Cappelliti; Luigi Lay
The invention provides a synthetic C. difficile PS-II cell wall saccharide. The invention also provides a process for purifying C. difficile PS-II saccharide from C. difficile bacterial cells resulting in reduced contamination. The saccharides may be used in vaccines, particularly as conjugates with carrier proteins.
167	GLUCOSAMINE MATERIALS	US13606260	2012-09-07	US20130109808A1	2013-05-02	Jennifer H. Elisseeff
Polymers comprising glucosamine (GlcN) are used to make medical devices. Examples include polyGlcN and carrier molecules containing multiple GlcN residues.
168	Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative	US12662184	2010-04-05	US08426382B2	2013-04-23	Remi Soula; Olivier Soula; Gerard Soula; Richard Charvet
The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.
169	SIALIC ACID DERIVATIVES	US13647326	2012-10-08	US20130096294A1	2013-04-18	Sanjay JAIN; Ioannis PAPAIOANNOU; Smita THOBHANI
An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids.
170	ACTIVATED SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION	US13544882	2012-07-09	US20130095548A1	2013-04-18	Sanjay JAIN; Ioannis PAPAIOANNOU; Smita THOBHANI
Derivatives of PSAs are synthesised, in which a reducing and/or non-reducing end terminal sialic acid unit is transformed into a N-hydroxysuccinimide (NHS) group. The derivatives may be reacted with substrates, for instance substrates containing amine or hydrazine groups, to form non-cross-linked/crosslinked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs, peptides or proteins or drug delivery systems.
171	Acidic composition	US12299110	2007-04-26	US08114910B2	2012-02-14	Earle John Loxton; Rudolph Johannes Malan; Stefan Coetzee
A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminum, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process.
172	SYNTHESIS OF HIGH MOLECULAR WEIGHT IRON-SACCHARIDIC COMPLEXES	US13108392	2011-05-16	US20110220539A1	2011-09-15	Robert A. Beck; Robert A. Mateer, JR.; John Kowalski
A process for preparing parenteral iron-saccharidic complexes, and the complexes produced, comprising: (1) providing an aqueous solution or dispersion including (i) Fe(III) and (OH)− ions and (ii) at least one saccharide, to form a reaction mixture, where the molar ratio of (i):(ii) is about 30:1 to about 1:30; and the mixture temperature and pH are at or above the complex assembly point (CAP); and (2) maintaining temperature and pH at or above the CAP for a time sufficient to form an iron-saccharidic complex having a molecular weight of about 25,000 Daltons or more. Control of the temperature and pH efficiently produces a high molecular weight complex. The complex can be separated by precipitation, dialysis and/or column fractionation and, if desired, dried, e.g., lyophilized or spray dried. The process can controllably synthesize complexes of varying molecular weight and/or chemical composition, particularly sodium ferric gluconate and ferric hydroxide-sucrose.
173	Anionic polysaccharides functionalized by a hydrophobic acid derivative	US12977690	2010-12-23	US20110172166A1	2011-07-14	Richard CHARVET; Remi SOULA; Olivier SOULA
A novel anionic polysaccharides functionalized by at least one hydrophobic acid derivative. These novel anionic polysaccharides including hydrophobic groups have good biocompatibility and their hydrophobicity can be easily adjusted without detrimentally affecting the biocompatibility or the stability. A method of synthesis which makes it possible to produce them and to pharmaceutical compositions including them.
174	REDUCTION OF ENDOTOXIN IN POLYSIALIC ACIDS	US12528763	2008-02-28	US20110159130A1	2011-06-30	Sanjay Jain; Peter Laing; Gregory Gregoriadis
The present invention relates to process for reducing the endotoxin content of a sample of fermentation broth containing polysialic acid and endotoxin comprising the sequential steps: (i) adding to the sample a base having a pKa of at least 12 to form a basic solution having a pH of at least 12, incubating the solution for a pre-determined time at a pre-determined temperature; and (ii) recovery of PSA, suitably by (iii) passing the sample through an anion-exchange column whereby polysialic acid is absorbed on the ion exchange resin; (iv) washing the column with one washing buffer, whereby polysialic acid remains absorbed on the ion exchange resin; and (v) eluting the polysialic acid from the column using an elution buffer to provide a product solution of polysialic acid having reduced endotoxin content.
175	SIALIC ACID DERIVATIVES FOR PROTEIN DERIVATISATION AND CONJUGATION	US12897523	2010-10-04	US20110082077A1	2011-04-07	Sanjay JAIN; Peter LAING; Gregory GREGORIADIS; Dale Howard HRECZUK-HIRST; Ioannis PAPAIOANNOU
Derivatives are synthesised of starting materials, usually polysaccharides, having sialic acid at the reducing terminal end, in which the reducing terminal unit is transformed into an aldehyde group. Where the polysaccharide has a sialic acid unit at the non-reducing end it may be passivated, for instance by converting into hydroxyl-substituted moiety. The derivatives may be reacted with substrates, for instance containing amine or hydrazine groups, to form non-cross-linked polysialylated compounds. The substrates may, for instance, be therapeutically useful drugs peptides or proteins or drug delivery systems.
176	AQUEOUS DISPERSION OF FRUCTAN-CONTAINING PARTICLES, METHOD OF PREPARATION AND USE	US12922418	2009-04-21	US20110020510A1	2011-01-27	Kim Martha Jozefa Frooninckx; Francois Alice Alphonso Heroufosse
The invention relates to an aqueous dispersion of fructan-containing particles, wherein the D50 of the fructan-containing particles lies between 2 μm and 50 μm and the solids content of the aqueous dispersion as a whole lies between 61 wt. % and 80 wt. %. The invention further relates to a process for the preparation of an aqueous dispersion of fructan-containing particles, comprising: a) the step of bringing fructan and water together to form a mixture; b) optionally a hydrolysis step, wherein a portion of the fructans in the mixture is hydrolysed, such that at the end of this step b) between 5 wt. % and 25 wt. % of all fructans in the mixture are essentially non-soluble at room temperature; c) optionally a purification step, wherein the mixture is brought into contact with a purification agent, followed by removal of the purification agent from the mixture; d) a concentrating step, wherein the mixture is concentrated, such that the solids content lies between 61 and 80%, whereby the aqueous dispersion is formed.
177	Sialic acid derivatives	US11660128	2005-08-12	US07875708B2	2011-01-25	Sanjay Jain; Ioannis Papaioannou; Smita Thobhani
An amine or hydrazide derivative of a sialic acid unit, e.g. in a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of N-hydroxy succinimide, to form an amide or hydrazide product. The product has a useful functionality, which allows it to be conjugated, for instance to proteins, drugs, drug delivery systems or the like. The process is of particular utility for derivatising amine groups introduced in sialic acid terminal groups of polysialic acids.
178	Polymer modified carbohydrate curable binder composition	US12660373	2010-02-25	US20100222459A1	2010-09-02	Michael DeWayne Kelly; Haksu Lee; Barry Weinstein
A curable aqueous binder composition comprising one or more amine reactant selected from the group consisting of: a protein, a peptide, an amino acid, an ammonium salt of a polycarboxylic acid, an ammonium salt of a (poly)hydroxy-(poly)carboxylic acid; one or more carbohydrate; and one or more emulsion polymer; and the use thereof as thermosetting binders. Also described are composite materials comprising the curable binder composition, and methods of application.
179	POLYSIALIC ACID DERIVATIVES	US12717073	2010-03-03	US20100221808A1	2010-09-02	Dale Howard Hreczuk-Hirst; Sanjay Jain; Peter Laing; Gregory Gregoriadis; Ioannis Papaioannou
A polysialic acid compound is reacted with a hetero-bifunctional reagent to introduce a pendant functional group for site-specific conjugation to sulfhydryl groups, for instance side chains of cysteine units in drugs, drug delivery systems, proteins or peptides. The functional group is, for instance, an N-maleimide group.
180	Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative	US12588149	2009-10-06	US20100167991A1	2010-07-01	Remi Soula; Olivier Soula; Gerard Soula; Richard Charvet
The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.

4 5 6 7 8 9 10 11 12 13

该功能需要专业版企业版VIP权限，您可以：